HKG:1061

2 stories mentioning HKG:1061Updated 14d ago

Every FINWIRES story that references HKG:1061, newest first.

Essex Bio-Technology Expects H1 Profit to Decline 30%

Essex Bio-Technology (HKG:1061) expects profit for the first half of 2026 to decline by approximately 30% from HK$163.4 million a year earlier, according to a Friday Hong Kong bourse filing.Revenue for the period is expected to decrease by approximately 10% from HK$876.5 million in the corresponding period of 2025.The company attributed the expected decline mainly to higher VAT expenses following the implementation of China's new VAT law.

HKG:1061

Asia45d ago

Henlius Biotech's Trial of Macular Degeneration Drug Meets Primary Endpoint

Shanghai Henlius Biotech's (HKG:2696) phase 3 study of HLX04-O in patients with wet age-related macular degeneration met its primary study endpoint, according to a Tuesday filing with the Hong Kong bourse.HLX04-O had a good safety profile, with similar overall, ocular and non-ocular safety results compared to ranibizumab.The drug is a new ophthalmic preparation product developed based on Hanbeitai, the exclusive rights of which for ophthalmic treatment and therapy worldwide have been granted by the company to Essex Bio-Technology (HKG:1061) and Zhuhai Essex Bio-Pharmaceutical.The company has an agreement to co-develop the relevant product with Essex Bio-Technology.

HKG:1061HKG:2696

Track with the FINWIRES app suite

FolioX

Track HKG:1061 in your portfolio

WheelAI

Analyze HKG:1061 options with the wheel strategy

StockInsider

See market sentiment on HKG:1061